Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2020

Filed with the SEC on Dec 11, 2020 and accepted by EDGAR at Dec 11, 2020, 16:47 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-08-01 to 2020-10-31$0us-gaap:Revenues
Revenue6 months2020-05-01 to 2020-10-31$0us-gaap:Revenues
Research and development3 months2020-08-01 to 2020-10-31$151.3kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-05-01 to 2020-10-31$421.9kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-08-01 to 2020-10-31−$949.5kus-gaap:OperatingIncomeLoss
Operating income6 months2020-05-01 to 2020-10-31−$1.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-08-01 to 2020-10-31$677us-gaap:InterestExpense
Interest expense6 months2020-05-01 to 2020-10-31$1.8kus-gaap:InterestExpense
Net income3 months2020-08-01 to 2020-10-31−$950.2kus-gaap:NetIncomeLoss
Net income6 months2020-05-01 to 2020-10-31−$1.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-08-01 to 2020-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2020-05-01 to 2020-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2020-08-01 to 2020-10-312,309,218,013 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2020-05-01 to 2020-10-311,993,895,090 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2020-05-01 to 2020-10-31−$1.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-10-31$3.7mus-gaap:Cash
Current assetsAt period end2020-10-31$3.8mus-gaap:AssetsCurrent
Total assetsAt period end2020-10-31$8.9mus-gaap:Assets
Current liabilitiesAt period end2020-10-31$643.6kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-10-31$664.7kus-gaap:Liabilities
Shareholders' equityAt period end2020-10-31$8.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-20-004267. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.